PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM

QR Code

PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM

Perampanel (PER) is a novel drug for treatment of refractory partial epilepsy in patients≥12 y.o. with proven efficacy and safety. PER is registered and may also be used successfully as adjunctive treatment in therapy of primary generalized tonic-clonic seizures (PGTCS).Objective. To determine the e...

Full description

Saved in:

Bibliographic Details
Main Authors:	N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2017-05-01
Series:	Фармакоэкономика
Subjects:	refractory partial onset epilepsy tonic-clonic seizures perampanel adjuvant therapy adverse event direct costs pharmacoeconomics pharmacoeconomic modeling
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/180
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Perampanel in the additional therapy of focal and primary generalized tonic-clonic seizures in children 4–12 years old: clinical data, experience of use and practical recommendations
by: K. Yu. Mukhin, et al.
Published: (2021-07-01)

Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures
by: Besag F, et al.
Published: (2016-05-01)

GENERALIZED TONIC-CLONIC SEIZURES : CLASSIFICATION, ELECTRO-CLINICAL CHARACTERISTICS, AND EFFICACY OF ANTIEPILEPTIC THERAPY
by: M. B. Mironov, et al.
Published: (2017-11-01)

The severity of seizures and epileptiform activity index in the assessment of antiepileptic treatment efficacy in patients with generalized tonic-clonic awakening seizures
by: V. A. Karlov, et al.
Published: (2021-10-01)

Bilateral tonic-clonic seizures and status epilepticus in autoimmune encephalitis
by: M. Yu. Maximova, et al.
Published: (2025-05-01)

Genetic Animal Models of Idiopathic Generalized Epilepsies: What Can We Learn from Them?
by: Bernard Lakaye, et al.
Published: (2025-05-01)

PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT
by: N. K. Mazina, et al.
Published: (2016-04-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Epilepsy combined with Wolf-Hirschhorn syndrome: a literature review and description of clinical cases
by: M. B. Mironov, et al.
Published: (2019-03-01)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2016-06-01)

Pharmacoeconomic effectiveness of phytotherapy in complex treatment of pyelonephritis
by: V. V. Ivanov, et al.
Published: (2015-04-01)

THE FEATURES OF METHODOLOGY FOR PHARMACOECONOMICS ANALYSIS OF VACCINATION
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

New possibilities of using perampanel in children. Efficacy and tolerability of perampanel in the treatment of epilepsy (literature review and experience of Svt. Luka’s Association of Medical Institutions)
by: K. Yu. Mukhin, et al.
Published: (2024-11-01)

PHARMACOECONOMIC ANALYSIS OF MARKET OF BIOLOGICALLY ACTIVE ADDITIVES MERCHANDIZED IN PHARMACY ORGANIZATIONS
by: O. V. Belousova, et al.
Published: (2015-12-01)

PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC STUDIES OF ANTIHYPERTENSIVE TREATMENT IN RUSSIA. Analytical Review
by: T. S. Romanenko, et al.
Published: (2015-09-01)

BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION
by: V. R. Mkrtchyan, et al.
Published: (2016-09-01)

PHARMACOECONOMICS OF APPLICATION OF HEPATOPROTECTORS IN THERAPY OF DRUG-INDUCED LIVER INJURY AFTER CHEMOTHERAPY
by: D. D. Morikov, et al.
Published: (2017-04-01)

Evolution of genetically determined generalized epilepsies
by: E. A. Morozova, et al.
Published: (2019-07-01)

PHARMACOECONOMIC ANALYSIS OF DIFFERENT METHODS FOR THE TREATMENT OF STEROID-REFRACTORY GRAFT-VERUS-HOST DISEASE: SINGLE-CENTER STUDY
by: I. S. Moiseev, et al.
Published: (2018-03-01)

Pharmacoeconomic aspects of COVID-19 treatment
by: I. V. Rogova, et al.
Published: (2021-10-01)

Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy
by: Tambucci R, et al.
Published: (2016-05-01)

PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION
by: V. A. Chibilyaev, et al.
Published: (2015-03-01)

PHARMACOECONOMIC STUDY OF SKIN TESTS IN THE DIAGNOSTICS OF TUBERCULOSIS INFECTION
by: R. I. Yagudina, et al.
Published: (2015-03-01)

PERAMPANEL (FYCOMPA) FOR TREATMENT OF EPILEPSY (EXPERIENCE OF THE SVT. LUKA'S INSTITUTE OF CHILD NEUROLOGY AND EPILEPSY)
by: K. Yu. Mukhin, et al.
Published: (2015-04-01)

PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
by: A. S. Kolbin, et al.
Published: (2015-03-01)

Pharmacoeconomic Analysis of the Use of Hepatoprotectors in Management of Drug-Associated Liver Injury Due to Hodgkin's Lymphoma Chemotherapy
by: D. D. Morikov, et al.
Published: (2020-05-01)

PERAMPANEL IN THE TREATMENT OF REFRACTORY EPILEPSY IN EVERYDAY CLINICAL PRACTICE IN ADOLESCENTS
by: S. G. Burd, et al.
Published: (2017-03-01)

THE STRUCTURE OF COSTS OF ANTIEPILEPTIC THERAPY ACCORDING TO THE DATA OF CENTER FOR CHILDREN WITH EPILEPSY
by: E. V. Shagrova, et al.
Published: (2015-07-01)

PHARMACOECONOMIC ANALYSIS OF ANTIHYPERTENSIVE DRUG COMBINATIONS USE
by: E. I. Tarlovskaya, et al.
Published: (2015-09-01)

COMPARATIVE PHARMACOECONOMIC STUDY OF VITAMIN-MINERAL COMPLEXES FOR REHABILITATION DURING THE PERIOD OF INCREASED NEEDS FOR MICRONUTRIENTS
by: A. Yu. Belinskaya, et al.
Published: (2015-12-01)

PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE
by: Yu. M. Lopatin, et al.
Published: (2015-08-01)

PHARMACOECONOMICS AS A NEW INSTRUMENT OF PHARMACEUTICAL MARKETING
by: M. V. Protsenko, et al.
Published: (2015-03-01)

PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA
by: A. V. Pavlysh, et al.
Published: (2015-03-01)

Perampanel in the treatment of drug-resistant epilepsy in children
by: M. Yu. Bobylova, et al.
Published: (2018-01-01)

COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS
by: M. B. Kubaeva, et al.
Published: (2017-08-01)

PHARMACOECONOMIC ANALYSIS OF CHICKENPOX IMMUNE PREVENTION EFFECTIVENESS IN THE INFANT ORPHANAGE INMATES
by: D. V. Raiskii, et al.
Published: (2014-11-01)

Pharmacoeconomics as an instrument of clinical pharmacology for optimization of pharmacotherapy (review)
by: O. V. Reshet'ko, et al.
Published: (2018-02-01)

Review of open libraries for pharmacoeconomic analysis in R environment
by: I. A. Lackman, et al.
Published: (2024-11-01)

CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation
by: A. A. Kurylev, et al.
Published: (2018-05-01)

Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis
by: I. I. Dyakov, et al.
Published: (2014-09-01)